ModiQuest discovers and develops novel antibody therapies and diagnostics for rheumatoid arthritis and cancer. We are focused on the early stages of research and drug discovery, involving the identification and validation of new therapeutic and diagnostic targets and the generation of monoclonal antibodies.
Our technologies and expertise include antibody generation, cloning, affinity maturation and humanisation; transient and stable cell line expression and antibody production, in vitro and in vivo bioassays to enable the development of fully characterised preclinical candidates. For further details on our services, visit http://www.modiquestresearch.com/technology/.
Currently our pipeline includes:
Mouse and human lead and backup molecules showing high reactivity against a novel validated target. Clear therapeutic efficacy in acute and chronic mouse models of rheumatoid arthritis and high tissue specificity in human ex vivo clinical samples. Currently available for out-licensing.
Rheumatoid arthritis diagnostics
Fully validated and licensed for clinical use as the anti-CCP test – the first diagnostic test for RA on the market. ModiQuest holds the patent for the diagnostic target and the diagnostic antibodies. Currently licensed by Euro-Diagnostica and Axis-Shield.
Novel antibody therapeutics for cancer
We have a number of proprietary oncology targets for immunotherapy which we are using to develop a series of novel antibody therapeutics.